AMENDMENTS TO THE CLAIMS

1. (Currently amended) The compounds according to the general formula Ia or Ib:

~~(FORMEL)~~



Ia



Ib

wherein in each

R1 means H, C_1-C_6 alkyl, cycloalkyl, **or** C_1-C_4 alkylcycloalkyl,

R2 means H, C_1-C_{14} alkyl, C_2-C_{14} alkenyl, aryl, C_1-C_4 alkylaryl, heteroaryl, C_1-C_4 alkylheteroaryl, C_2-C_4 alkenylheteroaryl, cycloalkyl, C_1-C_4 alkylcycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, $C_mH_{2m+o-p}Y_p$ (with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, **and** SH, SR21), $(CH_2)_rCH_2NHCOR21$, $(CH_2)_rCH_2OCOR21$, $(CH_2)_rCH_2NHCSR21$, $(CH_2)_rCH_2S(O)nR21$, with n = 0, 1, 2, $(CH_2)_rCH_2SCOR21$, $(CH_2)_rCH_2OSO_2$-R21, $(CH_2)_rCHO$, $(CH_2)_rCH=NOH$, $(CH_2)_rCH(OH)R21$, -$(CH_2)_rCH=NOR21$, $(CH_2)_rCH=NOCOR21$, $(CH_2)_rCH=NOCH_2CONR21R22$, $(CH_2)_rCH=NOCH(CH_3)CONR21R22$, $(CH_2)_rCH=NOC(CH_3)_2CONR21R22$, $(CH_2)_rCH=N$-NHCO-R23, $(CH_2)_rCH=N$-NHC(O)NH-R23, $(CH_2)_rCH=N$-NHC(S)NH-R23, $(CH_2)_rCH=N$-NHC(NH)NH-R23, $(CH_2)_rCH=N$-NHC(NH)-R23, $(CH_2)_rCH=N$-NHCO-CH_2NHCOR21, $(CH_2)_rCH=N$-O-CH_2NHCOR21, $(CH_2)_rCH=N$-NHCS-R23, $(CH_2)_rCH=CR24R25$ (trans or cis), $(CH_2)_rCOOH$, $(CH_2)_rCOOR21$, $(CH_2)_rCONR21R22$, -$(CH_2)_rCH=NR21$, $(CH_2)_rCH=N$-NR21R22,



~~(FORMEL)~~, and the $(CH_2)_r$-chain elongated residue $(CH_2)_rCH=N-N-(C_3NX'R211R212R213R214)$ (with X' = NR215, O, S, and R211, R212, R213, R214, R215 being independently H or C_1-C_6 alkyl), $-(CH_2)_rCH=N-NHSO_2$ aryl, **or** $-(CH_2)_rCH=N-NHSO_2$ heteroaryl, with r = 0, 1, 2, 3, 4, 5, ~~preferably 0,~~

R21, R22 are independently H, C_1-C_{14} alkyl, C_1-C_{14} alkanoyl, C_1-C_6 alkylhydroxy, C_1-C_6 alkoxy, C_1-C_6 alkylamino, C_1-C_6 alkylamino-C_1-C_6 alkyl, C_1-C_6 alkylamino-di-C_1-C_6-alkyl, cycloalkyl, C_1-C_4 alkylcycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, aryl, aryloyl, C_1-C_4 alkylaryl, heteroaryl, heteroaryloyl, C_1-C_4 alkylheteroaryl, cycloalkanoyl, C_1-C_4 alkanoylcycloalkyl, heterocycloalkanoyl, C_1-C_4 alkanoylheterocycloalkyl, C_1-C_4 alkanoylaryl, C_1-C_4 alkanoylheteroaryl, mono- and di-sugar residues linked through a C atom which would carry an OH residue in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereoisomers at all optical atoms, aldopentoses,

aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), or R21 and R22, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, **and** S,

R23 independently of R21, has the same meanings as R21, or CH_2-pyridinium salts, CH_2-tri-C_1-C_6 alkylammonium salts, $CONH_2$, $CSNH_2$, CN, **or** CH_2CN,

R24 independently of R21, has the same meanings as R21, or H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, **or** NHCOR21,

R25 independently of R21, has the same meanings as R21, or H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, **or** NHCOR21,

R24, R25 together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, **and** S,

R3 means H, F, Cl, Br, I, OH, OR31, NO_2, NH_2, NHR31, NR31R32, NHCHO, NHCOR31, $NHCOCF_3$, $CH_{3-m}hal_m$ (with hal = Cl, F, ~~particularly F,~~ and m = 1, 2, 3), **or** OCOR31,

R31, R32 are independently C_1-C_6 alkyl, or R31 and R32, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, **and** S,

R5 means H, C_1-C_{20} alkyl, cycloalkyl, C_2-C_{20} alkenyl, C_2-C_{10} alkinyl, C_1-C_4 alkylcycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, aryl, C_1-C_4 alkylaryl, heteroaryl, C_1-C_4 alkylheteroaryl, $C_mH_{2m+o-p}Y_p$ (with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR51, NH_2, NHR51, NR51R52, SH, SR21), $(CH_2)_sCH_2NHCOR51$, $(CH_2)_sCH_2NHCSR51$, $(CH_2)_sCH_2S(O)nR51$, with n = 0, 1, 2, $(CH_2)_sCH_2SCOR51$, $(CH_2)_sCH_2OCOR51$, $(CH_2)_sCH_2OSO_2$-R51, $(CH_2)_sCH(OH)R51$, $(CH_2)_sCOOH$, $(CH_2)_sCOOR51$, $(CH_2)_sCONR51R52$, with s = 0, 1, 2, 3, 4, 5, ~~preferably 0,~~ mono- and di-sugar residues linked through a C atom which would carry an OH residue in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereo isomers at all optical atoms, aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), with the mono-sugar residues such as aldopentoses, aldohexoses, including their desoxy compounds ~~(as e.g. glucose, desoxyglucose, ribose, desoxyribose) being preferred,~~ with R51, R52 which are capable of independently adopting the meaning of R21, R22,

R4, R6, R7 independently mean H, C_1-C_6 alkyl, CO-R41,

R41 independently from R21, has the same meanings as R21,

X means O, S, NH, N-R8, wherein R8 independently from R5 may adopt the same meaning as R5, or R5 and R8, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, **and** S,

or X-R5 may together be H,

Y means O, S, NR9, wherein R9 may be H or C_1-C_6 alkyl,

as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds, wherein the residues for Formula Ia may not concomitantly adopt the following meaning, except in case of cyclodextrin inclusion compounds: R1: H, C_1-C_6 alkyl, R2: C_1-C_6 alkyl, C_2-C_6 alkenyl, R3: H, R4 and R6 identical, and independently H, C_1-C_6 alkyl, CO-R41, with R41 being C_1-C_6 alkyl, aryl, and R7 being H, C_1-C_6 alkyl, Y: O, and for Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy, Y: O.

2. (Currently amended) The compounds according to claim 1, wherein Formula Ia or Ib adopts the stereochemistry of Formula IIa or IIb

~~(FORMEL)~~



II a



IIb

---

3. (Currently amended) The compounds of Formula Ia, Ib, IIa, IIb according to claim 2, ~~claim 1 or 2,~~ wherein ~~the residues R to R2 have the above indicated meanings, and wherein~~ R2 has a water solubility that is at least two times higher~~, preferably at least five times higher, more preferred at least ten times higher, particularly preferred at least fifty times higher, particularly hundred times higher, or even five hundred times higher~~ compared to R2 being CH=CH-CH=CH-CH_3, with all other residues being maintained.

4. (Currently amended) The compounds according to claim 1, ~~one of the claims 1 to 3,~~ wherein R3 means F, Cl, Br, I, OH, OR31, NO_2, NH_2, NHR31, NR31R32, NHCHO, NHCOR31, $NHCOCF_3$, $CH_{3-m}hal_m$ (with hal = Cl, F, ~~particularly F,~~ and m = 1, 2, 3), **or** OCOR31.

5. (Currently amended) The compounds according to claim 1, ~~one of the claims 1 to 4,~~ wherein R3 means $(CH_2)_rCHO$, $(CH_2)_rCH=NOH$, $-(CH_2)_rCH=NOR21$, $(CH_2)_rCH=NOCOR21$, $(CH_2)_rCH=NOCH_2CONR21R22$, $(CH_2)_rCH=NOCH(CH_3)CONR21R22$, $(CH_2)_rCH=NOC(CH_3)_2CONR21R22$, $(CH_2)_rCH=N-NHCO-R23$, $(CH_2)_rCH=N-NHC(O)NH-R23$, $(CH_2)_rCH=N-NHC(S)NH-R23$, $(CH_2)_rCH=N-NHC(NH)NH-R23$, $(CH_2)_rCH=N-NHC(NH)-R23$, $(CH_2)_rCH=N-NHCO-CH_2NHCOR21$, $(CH_2)_rCH=N-O-CH_2NHCOR21$, $(CH_2)_rCH=N-NHCS-R23$, $(CH_2)_rCH=CR24R25$ (trans or cis), $(CH_2)_rCH=NR21$, $(CH_2)_rCH=N-NR21R22$, ~~(FORMEL),~~



---

and the $(CH_2)_r$-chain elongated residue $(CH_2)_rCH=N-N-(C_3NX'R211R212R213R214)$ (with X' = NR215, O, S, and R211, R212, R213, R214, R215 being independently H or C_1-C_6 alkyl), $(CH_2)_rCH=N-NHSO_2$ aryl, $(CH_2)_rCH=N-NHSO_2$ heteroaryl, with r = 0, 1, 2, 3, 4, 5~~, preferably 0~~.

6. (Currently amended) The compounds according to claim 1, ~~one of the claims 1 to 5,~~ wherein X means N or S, or X-R5 is OH.

7. (Currently amended) The compounds according to claim1, ~~one of the claims 1 to 6,~~ wherein

R1 means H, C_1-C_5 alkyl, cycloalkyl, ~~especially H,~~

R2 means C_1-C_5 alkyl, C_1-C_4 alkylaryl, C_2-C_5 alkenyl, heteroaryl, C_1-C_4 alkylheteroaryl, CHF_2, CF_3, polyol side chain, ~~particularly CHOH-CHOH-CHOH-CHOH-CH_3, CHOH-CHOH-CH=CH-CH_3, CH=CH-CHOH-CHOH-CH_3,~~ CH_2Y (Y = F, Cl, Br, I), CH_2NH_2, $CH_2NR21R22$, $CH_2NHCOR23$, $CH_2NHCSR23$, CH_2SH, $CH_2S(O)_nR21$, with n = 0, 1, 2, $CH_2SCOR21$, ~~particularly~~ CH_2OH, CH_2OR21, CH_2OSO_2-R21, ~~particularly~~ CHO, $CH(OR21)_2$, $CH(SR21)_2$,

CN, CH=NOH, CH=NOR21, CH=NOCOR21, CH=N-NHCO-R32, CH=CR24, R25 (trans or cis), ~~particularly~~ COOH ~~(particularly their physiologically tolerable salts)~~, COOR21, CONR21R22, -CH=NR21, -CH=N-NR21R22,

~~(FORMEL),~~



(with X' = NR215, O, S, and R211, R212, R213, R214, R215 being independently H or C_1-C_6 alkyl), -CH=N-$NHSO_2$ aryl, -CH=N-$NHSO_2$ heteroaryl, **or** CH=N-NHCO-R23,

R21, R22 independently mean C_1-C_6 alkyl, cycloalkyl, aryl, C_1-C_4 alkylaryl, heteroaryl, **or** C_1-C_4 alkylheteroaryl,

R23 independently of R21, has the same meanings as R21, or CH_2-pyridinium salts, **or** CH_2-tri-C_1-C_6 alkylammonium salts,

R24 independently of R21, has the same meanings as R21, or H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, **or** NHCOR21,

R25 independently of R21, has the same meanings as R21, or H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, **or** NHCOR21,

R24, R25 together mean C_4-C_8 cycloalkyl,

R3 means F, Cl, Br, I, NO_2, NH_2, **or** NHCOR31,

R31 independently means C_1-C_6 alkyl,

R5 means H, C_1-C_6 alkyl, ~~particularly C_1-C_3-alkyl,~~ C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, C_1-C_6 alkenyl, C_1-C_6 alkinyl, C_1-C_4 alkylcycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, aryl, C_1-C_4 alkylaryl, heteroaryl, C_1-C_4 alkylheteroaryl, $C_mH_{2m+o-p}Y_p$ (with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH, SR21), ~~particularly preferred is~~ hydroxyalkyl with one or more OH groups,

R4, R6, R7 independently mean H, C_1-C_5 alkyl, **or** CO-R41,

R41 independently from R21, has the same meanings as R21,

X means O, S, NH, **or** N-R8,

Y means O, **or** S.

8. (Currently amended) The compounds according to claim 1 ~~one of the claims 1 to 7~~ in the form of inclusion compounds with cyclodextrin~~, particularly alpha-cyclodextrin~~.

9. (Currently amended) Drugs containing compounds according to claim 1, ~~one of the claims 1 to 8, as well as the usual carrier~~ **a carrier** and adjuvants.

10. (Original) Drugs according to claim 9 in combination with further agents for tumor treatment.

11. (Currently amended) **A preparation of drugs for tumor treatment which comprises using** ~~The use of~~ compounds according to claim 1 ~~one of the claims 1 to 8 for preparation of drugs for tumor treatment, particularly of those that can be treated by inhibition of the topoisomerases I and/or II, and by which apoptosis is induced~~.

12. (Currently amended) **A preparation of drugs for treatment of parasites which comprises using the** ~~The use of~~ compounds according to claim 1, ~~one of the claims 1 to 8,~~ or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: R1: H, C_1-C_6 alkyl, R2: C_1-C_6 alkyl, C_2-C_6 alkenyl, R3: H, R4 and R6 identical, and

independently H, C_1-C_6 alkyl, CO-R41, with R41 being C_1-C_6 alkyl, aryl, and R7 being H, C_1-C_6 alkyl, and in case of Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy~~, for preparation of drugs for treatment of parasites~~.

13. (Currently amended) **A preparation of drugs for immunosuppression which comprises the** ~~The use of~~ compounds according to claim 1, ~~one of the claims 1 to 8,~~ or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: R1: H, C_1-C_6 alkyl, R2: C_1-C_6 alkyl, C_2-C_6 alkenyl, R3: H, R4 and R6 identical, and independently H, C_1-C_6 alkyl, CO-R41, with R41 being C_1-C_6 alkyl, aryl, and R7 being H, C_1-C_6 alkyl, and in case of Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy~~, for preparation of drugs for immunosuppression~~.

14. (Currently amended) **A preparation of drugs for treatment of neurodermitis which comprises using** ~~The use of~~ compounds according to claim 1, ~~one of the claims 1 to 8,~~ or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: R1: H, C_1-C_6 alkyl, R2: C_1-C_6 alkyl, C_2-C_6 alkenyl, R3: H, R4 and R6 identical, and independently H, C_1-C_6 alkyl, CO-R41, with R41 being C_1-C_6 alkyl, aryl, and R7 being H, C_1-C_6 alkyl, and in case of Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X-R5 being methoxy~~, for preparation of drugs for treatment of neurodermitis~~.